Top Tweets for #Visugromab

4 months ago

GDF-15 and #visugromab confirm to be among the most attracting targets/agents for combination therapies in #urothelialcarcinoma (with EVP?). Here are the long-term results of the Phase I #GDFATHER01. Long-term neoadjuvant data are awaited (#GDFATHER-Neo). @urotoday @OncoAlert @DrIgMelero @SpringerNature @SanRaffaeleMI @MyUniSR https://t.co/6znHfF5d8S

AndreaNecchi's tweet photo. GDF-15 and #visugromab confirm to be among the most attracting targets/agents for combination therapies in #urothelialcarcinoma (with EVP?). Here are the long-term results of the Phase I #GDFATHER01. Long-term neoadjuvant data are awaited (#GDFATHER-Neo). @urotoday @OncoAlert @DrIgMelero @SpringerNature @SanRaffaeleMI @MyUniSR
https://t.co/6znHfF5d8S

Cancer Discovery @CD_AACR

almost 2 years ago

ICYMI: "GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition" https://t.co/3qi4irOY1W A #ResearchWatch summary of a study by @DrIgMelero, Eugen Leo, and colleagues @ClinicaNavarra @CIMA_unav #visugromab #CatalYm

CD_AACR's tweet photo. ICYMI: "GDF-15 Blockade Overcomes Resistance to Immune Checkpoint Inhibition" https://t.co/3qi4irOY1W
A #ResearchWatch summary of a study by @DrIgMelero, Eugen Leo, and colleagues @ClinicaNavarra @CIMA_unav #visugromab #CatalYm https://t.co/OtnimSU1hK

Andrea Necchi, MD, FASCO

@AndreaNecchi

almost 3 years ago

Eugen Leo #Catalym presents the basic science leading to clinical developments of anti-GDF-15 in solid tumors including bladder cancer #GDFather #Visugromab #NeoGDFather @SanRaffaeleMI @MyUniSR

AndreaNecchi's tweet photo. Eugen Leo #Catalym presents the basic science leading to clinical developments of anti-GDF-15 in solid tumors including bladder cancer #GDFather #Visugromab #NeoGDFather @SanRaffaeleMI @MyUniSR https://t.co/jldqtToaSp

470

Andrea Necchi, MD, FASCO

@AndreaNecchi

over 3 years ago

#GDF-15 #visugromab development is a promising challenge in IO-refractory solid tumors. Congrats Ignacio Melero & #Catalym team! NEO-GDFather trial in #MIBC opening soon IN 🇮🇹 #ASCO23

$AndreaNecchi's tweet photo. #GDF-15 #visugromab development is a promising challenge in IO-refractory solid tumors. Congrats Ignacio Melero & #Catalym team! NEO-GDFather trial in #MIBC opening soon IN 🇮🇹 #ASCO23 https://t.co/Ymn9Gz0spd$

940

BioM Biotech Cluster Development @BioM_Munich

almost 4 years ago

👏 Wow! Martinsried-based #biotech start-up #CatalYm has successfully closed a Series C financing of 50 million euros. This will be used to advance the Phase 2 clinical development of #visugromab in patients with solid #tumors. ▶️ https://t.co/wqJTbPZuDD

Top Tweets for #Visugromab

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users